For years, employers have managed benefits around a familiar annual rhythm.
That rhythm isn't going away. Annual planning still matters. It's when major decisions get made, budgets are finalized, vendors are evaluated, and benefit strategies are communicated.
But specialty medication spend has changed the equation.
High-cost medications don't wait for renewal. A new diagnosis, a new prescription, a therapy change, a new indication, or a shift in utilization can happen at any point in the plan year. And when it does, the financial impact can be immediate and significant.
That's the challenge employers are facing now. Specialty spend has become too dynamic, too expensive, and too member-sensitive to be managed only once a year.
The old benefits calendar no longer matches the reality of the risk.
Many parts of the benefits program can be evaluated on an annual cycle because the changes are broader, more predictable, or easier to plan around.
Specialty medications are different.
A small number of claims can drive a meaningful portion of total pharmacy spend. One new therapy can materially change the economics of a plan. One member's medication journey can involve the employer, the PBM, the consultant, the pharmacy, the provider, the manufacturer, and the member's family.
That complexity doesn't wait politely for renewal with a binder and a calendar invite.
And too often, employers only see the full impact after the cost has already hit the plan. By the time the issue becomes part of the renewal conversation, the opportunity to act earlier may already be gone.
That's not a criticism of the renewal process. Renewal is important, but it shouldn't be the first time an employer asks whether their pharmacy strategy is working.
When specialty pharmacy strategy is limited to annual planning, employers can spend months absorbing costs that may've been manageable with earlier intervention. Just as importantly, unexpected specialty utilization can create budget volatility throughout the year, leaving HR, finance, consultants, and vendor partners trying to explain surprises at renewal rather than addressing them when they emerge.
Finance teams feel it in the budget. HR teams feel it in employee questions. Consultants and partners are left explaining trend after the dollars have already moved through the plan.
This isn't only a financial issue. There's a member experience issue as well.
When there's no active strategy in place, members can be left navigating expensive, confusing, and often emotional treatment decisions without enough guidance. They may not understand their options. They may not know who to call. They may face delays, denials, confusing outreach, or a process that feels more like a maze than a benefit.
That matters because the success of any pharmacy strategy depends on whether members can actually use it.
Projected savings don't mean much if the pathway is too confusing, too slow, or too impersonal for members to engage with.
The employers that manage specialty spend most effectively will be the ones that move from episodic pharmacy management to active pharmacy management.
That doesn't mean chasing every claim. It doesn't mean creating disruption for the sake of disruption. And it doesn't mean every issue requires a dramatic mid-year plan change.
It means building the discipline to identify, evaluate, and respond when action matters.
A more active pharmacy strategy includes ongoing visibility into high-cost medication activity. It includes early identification of opportunities. It includes coordination across PBMs, consultants, TPAs, clinical partners, and member support teams. It includes clear communication. And it includes accountability for what actually happens, not just what could happen in a model.
Employers should be able to answer basic questions throughout the year:
Where's high-cost pharmacy spend emerging?
Which opportunities are actionable?
Which interventions require renewal timing, and which can happen now?
What support does the member need?
What savings were projected?
What savings were actually realized?
Are members adequately supported?
Those questions shouldn't be reserved for the annual review.
They should be part of an ongoing operating model.
There's a good reason many employers push pharmacy strategy into the annual planning cycle.
That's how benefits have traditionally worked.
Plan changes can be disruptive. Member communication takes planning. Consultants, PBMs, TPAs, HR teams, and finance teams all need to be aligned. Nobody wants to create confusion in the middle of the year, especially when members are dealing with serious conditions and expensive medications.
So the natural response is often simple: “We should wait until renewal.”
That instinct is understandable. But it isn't always right.
Not every pharmacy cost strategy requires a disruptive plan change. Not every intervention has to wait for a new plan year. In many cases, employers can take measured, member-friendly steps during the year that improve support, create new options, and reduce unnecessary spend.
The key is knowing the difference.
Some changes should wait for renewal. Others shouldn't. A modern pharmacy strategy should help employers make that distinction clearly and responsibly.
High-cost medications aren't just expensive line items. They're tied to people who may be facing serious diagnoses, stress, uncertainty, and urgent questions about their care.
That reality should shape how employers approach pharmacy cost management.
If a program feels confusing, forced, or impersonal, members may not engage. If members don't trust the process, they may avoid it. If they don't understand the value, they may ignore the outreach altogether.
And when that happens, the savings remain theoretical.
The best pharmacy strategies reduce cost while making the experience feel more supported, not less. Members need clear explanations. They need practical guidance. They need a human being who can answer questions. They need to understand what's happening and why it matters.
That's not just good service.
It's central to whether the strategy works.
Savings are only real when members can actually use the pathway.
Employers should expect more from their pharmacy strategy than an annual review and a renewal recommendation.
They should expect visibility throughout the year. They should expect actionable recommendations. They should expect a clear distinction between projected savings and realized savings.
They should expect coordination across the vendors and stakeholders already involved in the plan. They should expect member communication that's clear, human, and practical. They should expect flexibility to act before the next renewal when appropriate.
Most importantly, they should expect accountability.
The benchmark should be whether the employer has a working system that identifies opportunities and supports members.
A system that measures outcomes and can respond when pharmacy spend changes, not twelve months later.
Annual planning will always have a place in benefits strategy. But it can't be the only moment when pharmacy gets attention.
Specialty medication spend has become too material, too fast-moving, and too member-sensitive for employers to manage passively. Employers need a working model that can identify opportunities, support members appropriately, coordinate stakeholders, and provide consistent outcomes throughout the year.
For self-funded employers, the question is no longer whether pharmacy strategy matters.
It is whether the strategy is active enough to respond when the risk actually shows up.
Tyler Mamiya is the Founder and CEO of Rescrybe, which helps self-funded employers reduce specialty drug costs, support employees through every step, and generate savings that stand up to scrutiny.
